The global landscape of vaccine manufacturing is undergoing a significant transformation, particularly in low and middle-income countries (LMICs).
Local manufacturers in countries like Brazil, Kenya, and Senegal are playing an increasingly important role in vaccine production.
The World Health Organization (WHO) has initiated a technology transfer program to equip LMICs with the capacity to produce their own vaccines.
This program aims to address the inequities in vaccine access that were highlighted during the COVID-19 pandemic.
Collaborative efforts, such as research and development consortia, have been established to ensure manufacturers have access to a diverse portfolio of products.
The WHO's mRNA vaccine program focuses on sustainability and aims to establish a robust manufacturing capacity in LMICs.
Financial challenges remain, and manufacturers are exploring blended finance models to secure ongoing funding.
The efforts to enhance vaccine manufacturing in LMICs aim to achieve health equity on a global scale and create a more resilient healthcare infrastructure.